Regulation of peroxisome proliferator-activated receptor gamma (PPARg) activity is the result of several events. The first control level is the regulation of the expression of PPARg. Examples of this regulation, during adipogenesis, is the transactivation of the PPARg promoter by transcription factors of the classical pathway, such as C/EBPs or ADD1/SREBP1, but also newly identified factors, such as E2Fs. When preadipocytes re-enter the cell cycle, PPARg expression is induced coincident with an increase in DNA synthesis, suggesting the involvement of the E2F family of cell cycle regulators. E2F1 induces PPARg transcription during clonal expansion, whereas E2F4 represses PPARg expression during terminal adipocyte differentiation. Hence, E2Fs represent the link between proliferative signaling pathways, triggering clonal expansion, and terminal adipocyte differentiation through regulation of PPARg expression. A second regulatory level of PPARg action is interaction with cofactors. We will focus our attention on the atypical PPARg modulators. We have described an interaction between PPARg and the retinoblastoma protein, RB, which is both dependent upon ligand binding by PPARg and upon the phosphorylation status of RB. The interaction between PPARg and RB decreases the transcriptional activity of PPARg through recruitment of the histone deacetylase HDAC3. Inhibition of HDAC activity consequently results in a strong activation of PPARg.
PPARc
Peroxisome proliferator-activated receptor gamma (PPARg) is a member of the hormone nuclear receptor super family whose activity is regulated by ligands. Naturally occurring fatty acids, such as linoleic acid, and fatty acid derivatives, such as prostaglandin J2 and the antidiabetic drugs, thiazolidinediones, have been determined as natural and synthetic ligands of PPARg. PPARg plays a central role in the adipocyte differentiation process, through regulation of the expression of adipocyte-specific genes, such as aP2, fatty acid transport protein-1 (FATP-1), or lipoprotein lipase (LPL), which are involved in lipid storage and control of metabolism. 1 Genetic studies both in humans and mice have demonstrated the crucial role that PPARg plays in adipogenesis. PPARg-deficient mice are devoid of adipose tissue, and PPARg þ /À mice are characterized by a decreased adipose tissue mass. 2, 3 In humans, several mutations in the PPARg gene have so far been described (reviewed in Debril et al
. A rare Pro115Gln mutation in the NH 2 -terminal ligand-independent activation domain of PPARg results in a constitutively active PPARg leading to increased adipocyte differentiation and obesity. 5 A much more common Pro12A-la substitution in the PPARg2-specific exon B, resulting in a less active PPARg form, is associated with a lower BMI. 6 Since PPARg activity has dramatic effects on lipids and glucose homeostasis, much effort has been directed to study how PPARg activity is modulated. At least three different levels are revealed to be important in PPARg activity modulation. First, ligand-binding modifies the conformation of PPARg, regulating its transcriptional activity. Second, regulation of the PPARg mRNA transcription increases or decreases PPARg protein concentration. Finally, cofactor interactions result in the activation or repression of PPARg target gene transcription. In this review, we will discuss some atypical factors regulating PPARg expression or activity.
Regulation of PPARc expression
Most of our knowledge about the regulation of PPARg expression comes from observations during the in vitro differentiation of fibroblastic cell lines, such as 3T3-L1 preadipocytes, or primary adipocyte precursors into adipocytes. In these in vitro models, terminal adipocyte differentiation starts after fibroblastic precursor cells become contact inhibited in their growth. Those cells then re-enter the cell cycle after appropriate hormonal induction, in a process termed clonal expansion. Subsequently, cells arrest this second proliferation phase again and undergo terminal adipocyte differentiation in a process leading to lipids accumulation. Several families of transcription factors activate or repress PPARg mRNA expression during adipogenesis. Inhibitors include transcription factors of the GATA family. In particular, constitutive expression of GATA-2 and GATA-3 was shown to decrease PPARg expression and, as a consequence, inhibition of adipocyte differentiation. 7 Other transcription factors, such as TCF4, a transcriptional mediator of the Wnt pathway, were suggested to repress PPARg and C/EBPa expression in preadipocytes. 8 Among the activators of PPARg expression, the CCAAT enhancer-binding proteins (C/EBP) are possibly the most studied. C/EBPb and d are induced in response to adipogenic hormones such as insulin or glucocorticoids, and directly induce the transcription of PPARg during the first phases of adipogenesis. 9 Other transcription factors that are also involved in triggering PPARg expression early in adipogenesis include the basic helix-loop-helix protein adipocyte determination and differentiation factor 1/sterol regulatory element-binding protein-1 (ADD-1/SREBP-1), which can induce PPARg transcription through binding to response elements in the PPARg1 and g3 promoter regions. 10 While several other transcription factors might regulate PPARg promoters during terminal adipocyte differentiation, our research has focused on the transcriptional regulation of PPARg expression during the transition between cell proliferation and adipocyte differentiation, that is, during the clonal expansion phase. As in most cells, the transition from growth-arrested preadipocytes into S-phase likely depends on the reactivation of the G1 cyclins/cdks and the pocket proteins-E2F pathway that controls the G1/S transition of the cell cycle. Interestingly, we noticed that PPARg is expressed as soon as the cells enter into the clonal expansion phase of adipogenesis. This suggested that transcription factors that regulate re-entry into cell cycle could also trigger PPARg expression. One of the crucial transcriptional regulators of the cell cycle is the E2F family of transcription factors. Consistent with this function, an increase in E2F activity has been observed during the first hours of adipocyte differentiation.
11,12 E2F DNA-binding sites were found to be critical in the promoters of genes involved in cell cycle progression, apoptosis, and DNA synthesis (for reviews, see Nevins
13
, Helin 14 and Sardet et al 15 ) . When bound to DNA, they exist either as free E2F/DP heterodimers, or associated in larger complexes containing members of the retinoblastoma family (pRB, p107, p130) and members of the cyclin/cdk protein families. E2F complexes can act as repressors (E2F4-5) or as activators (E2F1-3) of their target genes. E2F4 and E2F5 are especially relevant in the process of transition from cell proliferation to differentiation. In growth-arrested preadipocytes, p130 is complexed with E2F4 and E2F5, leading to repression or inactivation of its target genes. Upon re-entry into cell cycle, p130 as well as the other members of the retinoblastoma family are phosphorylated by the cyclin/cdk holoenzymes, releasing the E2F complex, resulting in the activation of the E2F target genes. 11 After several rounds of DNA synthesis, the cyclin-dependent kinase inhibitors such as p21, p27, or p18 are induced and mediate the exit from the cell cycle and the maintenance of the irreversible growth arrest characteristic of terminal differentiation. 16 
Regulation of PPARc activity
The proteins called 'cofactors' play an important role in transcriptional control. Such cofactors interact with nuclear receptors and they can either repress (corepressors) or enhance (coactivators) their transcriptional activities. 17 Members of three groups of coactivators, that is, the p160 steroid receptor coactivator family (SRC), CBP/p300, and the p300/CBP-associated factor (p/CAF)/GCN family, as well as other coactivators such as PGC1, have been reported to interact with PPARg and increase its activity. In contrast, corepressors such as the silencing mediator for retinoid and thyroid hormone receptors (SMRT) and nuclear receptor co-repressor (NCoR) repress PPARg-mediated transcription (reviewed in Auwerx   18 ). Here, however, we will discuss newly identified atypical PPARg cofactors.
While studying the modulation of PPARg activity during adipogenesis, we found that PPARg promotes adipocyte differentiation more efficiently in the absence of the retinoblastoma protein RB. 19 The role of the retinoblastoma protein family members, or the pocket proteins pRB, p130, and p107, in adipocyte differentiation is still controversial. The negative role of pocket proteins in cell cycle progression, repressing the expression of the E2F target genes, has been demonstrated in several settings. Pocket proteins are inactivated by phosphorylation by the cyclin-dependent kinases, resulting in the activation of the E2F target genes. Consistent with an active cell cycle in the early stages of PPARc and atypical factors S Miard and L Fajas adipogenesis, pocket proteins have been found to be hyperphosphorylated following hormonal induction of preadipocytes. 11 However, an apparent paradox arises from the finding that pRB inactivation, by SV40 large T antigen, inhibits adipogenesis. 20 Moreover, pRB-deficient fibroblasts fail to differentiate into adipocytes when properly stimulated. 21 This apparent paradox was explained by the participation of RB in the growth arrest following clonal expansion. But the negative effect of RB on adipogenesis goes further than the control of the clonal expansion phase. The observed increase in adipogenesis in the presence of PPARg ligands and in the absence of RB was the result of the attenuation of PPARg's capacity to drive gene expression and adipocyte differentiation by a repressor complex formed by PPARg, RB, and the histone deacetylase HDAC3. Dissociation of the PPARg-RB-HDAC3 complex by RB phosphorylation or by inhibition of HDAC activity stimulates adipocyte differentiation. 19 Clearly, more in vivo studies, such as the ones utilizing adipose tissue-specific RB knockout mice, are required to elucidate the role of RB in adipogenesis.
Conclusions
Besides typical transcription factors and cofactors, a new role for previously unsuspected PPARg regulators has emerged. These atypical factors are mainly involved in cell cycle and cell proliferation regulation. By modulating PPARg activity or expression, they have become new actors in the control of metabolism, establishing a new link between cell proliferation and cell differentiation (Figure 1 ). External signaling, such as nutrition or stress, is indeed a proliferative signal. Cell cycle regulators, such as E2Fs and RB, modulate the expression and activity of PPARg, which will finally mediate a metabolic response by the cell.
